TenX Biopharma Licenses Zanolimumab from Genmab
TenX Biopharma, Inc. (Philadelphia, PA) has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4) from Genmab A/S (Copenhagen, Denmark).
TenX Biopharma, Inc. (Philadelphia, PA) has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4) from Genmab A/S (Copenhagen, Denmark).
Zalutumumab is a fully human, high-affinity antibody targeted at the epidermal growth factor receptor (EGFr) and is in clinical development to treat head and neck cancer. EGFr is a receptor molecule found on the surface of many cancer cells. Activation of EGFr by the appropriate growth factor molecule promotes the growth of tumor cells.
Based on data from clinical cancer trials conducted by other biotechnology and pharmaceutical companies using both anti-EGFr antibodies and small-molecule drugs, Genmab believes that an antibody targeting EGFr may be an effective treatment for a variety of cancers, particularly when used in combination with chemotherapy or radiation.
Zalutumumab has been awarded Fast Track status from the FDA covering head and neck cancer patients who have previously failed standard therapies.
Under the terms of the agreement, Genmab will receive an upfront license fee of $4.5 million and will be entitled to milestones and royalties on sales of zanolimumab. TenX will be responsible for all future costs of developing, manufacturing, and commercializing zanolimumab.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
